NO175856B - - Google Patents

Download PDF

Info

Publication number
NO175856B
NO175856B NO911419A NO911419A NO175856B NO 175856 B NO175856 B NO 175856B NO 911419 A NO911419 A NO 911419A NO 911419 A NO911419 A NO 911419A NO 175856 B NO175856 B NO 175856B
Authority
NO
Norway
Prior art keywords
acid
group
formula
mmol
hydroxymethyl
Prior art date
Application number
NO911419A
Other languages
English (en)
Norwegian (no)
Other versions
NO911419D0 (no
NO911419L (no
NO175856C (no
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of NO911419D0 publication Critical patent/NO911419D0/no
Publication of NO911419L publication Critical patent/NO911419L/no
Publication of NO175856B publication Critical patent/NO175856B/no
Publication of NO175856C publication Critical patent/NO175856C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/44—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton bound to carbon atoms of the same ring or condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
NO911419A 1990-04-12 1991-04-11 Analogifremgangsmåte for fremstilling av nye - og fucosidase-inhibitorer NO175856C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50887590A 1990-04-12 1990-04-12

Publications (4)

Publication Number Publication Date
NO911419D0 NO911419D0 (no) 1991-04-11
NO911419L NO911419L (no) 1991-10-14
NO175856B true NO175856B (enExample) 1994-09-12
NO175856C NO175856C (no) 1994-12-21

Family

ID=24024437

Family Applications (1)

Application Number Title Priority Date Filing Date
NO911419A NO175856C (no) 1990-04-12 1991-04-11 Analogifremgangsmåte for fremstilling av nye - og fucosidase-inhibitorer

Country Status (19)

Country Link
EP (1) EP0451834B1 (enExample)
JP (1) JP2955057B2 (enExample)
KR (1) KR100197382B1 (enExample)
CN (1) CN1033638C (enExample)
AT (1) ATE140692T1 (enExample)
AU (1) AU646855B2 (enExample)
CA (1) CA2040058C (enExample)
DE (1) DE69121000T2 (enExample)
DK (1) DK0451834T3 (enExample)
ES (1) ES2092520T3 (enExample)
FI (1) FI109200B (enExample)
GR (1) GR3020934T3 (enExample)
HU (1) HU213396B (enExample)
IE (1) IE75195B1 (enExample)
IL (1) IL97814A (enExample)
NO (1) NO175856C (enExample)
NZ (1) NZ237734A (enExample)
PT (1) PT97339B (enExample)
ZA (1) ZA912588B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773239A (en) * 1993-10-19 1998-06-30 Mount Sinai Hospital Corporation. Mannosidase inhibitors, process for their preparation and their use as therapeutic agents
US5650413A (en) * 1995-06-07 1997-07-22 Glycodesign Inc. Derivatives of swainsonine, processes for their preparation and their use as therapeutic agents
WO1998014446A1 (en) * 1996-10-01 1998-04-09 Glycodesign Inc. Novel 3, 5, and/or 6 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents
US6395745B1 (en) 1997-04-15 2002-05-28 Glycodesign, Inc. Alkaloid halide salts of swainsonine and methods of use
WO1999021858A1 (en) * 1997-10-24 1999-05-06 Glycodesign Inc. Synthesis of swainsonine salts
KR101784539B1 (ko) * 2010-01-28 2017-10-11 랩터 파마슈티컬스 인코포레이티드 수용체 결합 단백질(ｒａｐ) 펩타이드-푸코시다제 억제제 접합체를 이용한 간 질환의 치료방법
CN101870992A (zh) * 2010-06-21 2010-10-27 天津科技大学 利用基因工程菌耦合发酵合成gdp-岩藻糖的方法
CN102286608B (zh) * 2011-06-08 2014-06-25 郑州安图生物工程股份有限公司 衣原体诊断方法和试剂盒

Also Published As

Publication number Publication date
IE911229A1 (en) 1991-10-23
HU911196D0 (en) 1991-10-28
NZ237734A (en) 1993-05-26
CA2040058A1 (en) 1991-10-13
HUT60994A (en) 1992-11-30
FI109200B (fi) 2002-06-14
IL97814A (en) 1995-08-31
AU7416491A (en) 1991-10-17
NO911419D0 (no) 1991-04-11
FI911751L (fi) 1991-10-13
IE75195B1 (en) 1997-08-27
JP2955057B2 (ja) 1999-10-04
DK0451834T3 (da) 1996-08-26
NO911419L (no) 1991-10-14
GR3020934T3 (en) 1996-12-31
ES2092520T3 (es) 1996-12-01
HU213396B (en) 1997-06-30
DE69121000T2 (de) 1996-12-19
DE69121000D1 (de) 1996-08-29
CA2040058C (en) 2001-10-23
JPH04234834A (ja) 1992-08-24
NO175856C (no) 1994-12-21
ZA912588B (en) 1992-01-29
FI911751A0 (fi) 1991-04-11
PT97339B (pt) 1998-08-31
EP0451834A2 (en) 1991-10-16
ATE140692T1 (de) 1996-08-15
CN1055732A (zh) 1991-10-30
PT97339A (pt) 1992-01-31
EP0451834A3 (en) 1993-10-20
EP0451834B1 (en) 1996-07-24
CN1033638C (zh) 1996-12-25
KR100197382B1 (ko) 1999-06-15
IL97814A0 (en) 1992-06-21
AU646855B2 (en) 1994-03-10
KR910018341A (ko) 1991-11-30

Similar Documents

Publication Publication Date Title
CZ124494A3 (en) Process for preparing ester of prolineboric acid, intermediate employed in this process and process for preparing such intermediate
JP2001527058A (ja) ノイラミニダーゼ阻害剤として有用な置換シクロペンタン及びシクロペンテン化合物
RU2241001C2 (ru) Производные галантамина, способ их получения, лекарственное средство на их основе и способ его получения
CZ63799A3 (cs) Spirocyklické metalloproteázové inhibitory
EP1167354A2 (en) Racemic huperzine A
Li et al. L-DMDP, L-homoDMDP and their C-3 fluorinated derivatives: synthesis and glycosidase-inhibition
NO175856B (enExample)
US5240707A (en) Alpha-mannosidase and fucosidase inhibitors
US12378246B2 (en) Synthetic options towards the manufacture of (6R,10S)-10-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl} - 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one
FI70009C (fi) Foerfarande foer framstaellning av nya 1,5-disubstituerad-2-pyrrolidonfoereningar vilka har prostaglandinliknande biologiska egenskaper
JP2004010617A (ja) アザ二環式ロートマーゼ阻害剤
AU617041B2 (en) Anti-inflammatory 6-substituted amino benzoxazolin-2-one derivatives
EP0449294A1 (en) Hydroxymethyl-indolizidines and quinolizidines
JP3435692B2 (ja) シアタン誘導体
RU2815806C2 (ru) Бициклические гетероарильные производные
JP7326623B2 (ja) イソインドリノン誘導体の調製方法、それに用いられる新規な中間体、及びその調製方法
Koemans Design of branched swainsonines as selective Golgi alpha-mannosidase II inhibitors
Kiyota et al. Synthesis of southern (C1'-C11') and eastern (C8-C18) fragments of pamamycin-607, an aerial mycelium-inducing substance of Streptomyces alboniger
SU1189351A3 (ru) Способ получени 5 @ -/2 @ -бутил/-пептидэрготалкалоида или его аддитивных солей с кислотами
EP0664293A1 (en) 2-Phenyl-7-azabicycloheptanes and 6-phenyl-8-azabicyclo
Alyamani Method development towards the synthesis of the alkaloid Alexine using 3-alkoxy, 3-acyloxy or 3-trialkylsilyl allyl organo indium, zinc, or boron reagents
Wunder et al. An expeditious synthesis of the ascomycete metabolite rigidiusculamide B
Smith Part 1. Progress Towards an Improved Total Synthesis of Azaspirene, a Powerful Angiogenesis Inhibitor Part 2. Copper Catalyzed Conjugate Silyl Additions to Enones
KR830000329B1 (ko) 스피로-옥사졸리딘디온의 제조방법
Xia Total synthesis of (+,-)-huperzine A; synthesis of (-)-1D-3-deoxy-3-fluoro-myo-inositol; and model studies toward the total synthesis of the rubradirins